© 1991 by Oxford University Press
Breast Cancer Prognostic Factors: Evaluation Guidelines
William L. McGuire
| You have reached the most complete version of this article accessible without further authentication.
More complete versions are available. Link to article |
Article topics:
- Medicine..Breast Issues
- Oncology..Treatment Options for Breast Cancer
- Oncology..Breast Cancer
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  V. Pelekanou, M. Kampa, M. Kafousi, K. Dambaki, K. Darivianaki, T. Vrekoussis, E. Sanidas, D. D. Tsiftsis, E. N. Stathopoulos, and E. Castanas Erythropoietin and Its Receptor in Breast Cancer: Correlation with Steroid Receptors and Outcome Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2016 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Xenidis, V. Markos, S. Apostolaki, M. Perraki, A. Pallis, G. Sfakiotaki, D. Papadatos-Pastos, L. Kalmanti, M. Kafousi, E. Stathopoulos, et al. Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer Ann. Onc., October 1, 2007; 18(10): 1623 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-S. Ko, Y.-S. Na, C.-S. Yoon, J.-Y. Park, H.-S. Kim, M.-H. Hur, H.-K. Lee, Y.-K. Chun, S.-S. Kang, B.-W. Park, et al. The Significance of c-erbB-2 Overexpression and p53 Expression in Patients With Axillary Lymph Node--Negative Breast Cancer: A Tissue Microarray Study International Journal of Surgical Pathology, April 1, 2007; 15(2): 98 - 109. [Abstract] [PDF]
|
|
|
|
 |
|
 M. C.U. Cheang, D. O. Treaba, C. H. Speers, I. A. Olivotto, C. D. Bajdik, S. K. Chia, L. C. Goldstein, K. A. Gelmon, D. Huntsman, C. B. Gilks, et al. Immunohistochemical Detection Using the New Rabbit Monoclonal Antibody SP1 of Estrogen Receptor in Breast Cancer Is Superior to Mouse Monoclonal Antibody 1D5 in Predicting Survival J. Clin. Oncol., December 20, 2006; 24(36): 5637 - 5644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Visvanathan, S. Sukumar, and N. E. Davidson Epigenetic Biomarkers and Breast Cancer: Cause for Optimism. Clin. Cancer Res., November 15, 2006; 12(22): 6591 - 6593. [Full Text] [PDF]
|
|
|
|
|
|
L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, and G. M. Clark Reporting Recommendations for Tumor Marker Prognostic Studies J. Clin. Oncol., December 20, 2005; 23(36): 9067 - 9072. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Brenton, L. A. Carey, A. A. Ahmed, and C. Caldas Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application? J. Clin. Oncol., October 10, 2005; 23(29): 7350 - 7360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, G. M. Clark, and for the Statistics Subcommittee of the NCI-EORTC W Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) J Natl Cancer Inst, August 17, 2005; 97(16): 1180 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. McShane, D. G. Altman, and W. Sauerbrei Identification of Clinically Useful Cancer Prognostic Factors: What Are We Missing? J Natl Cancer Inst, July 20, 2005; 97(14): 1023 - 1025. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Sargent, B. A. Conley, C. Allegra, and L. Collette Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials J. Clin. Oncol., March 20, 2005; 23(9): 2020 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Oliveira and C. D.M. Fletcher Molecular Prognostication for Soft Tissue Sarcomas: Are We Ready Yet? J. Clin. Oncol., October 15, 2004; 22(20): 4031 - 4034. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Baider, E. Andritsch, G. Goldzweig, B. Uziely, P. Ever-Hadani, G. Hofman, G. Krenn, and H. Samonigg Changes in Psychological Distress of Women With Breast Cancer in Long-Term Remission and Their Husbands Psychosomatics, February 1, 2004; 45(1): 58 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Manders, F. C. G. J. Sweep, V. C. G. Tjan-Heijnen, A. Geurts-Moespot, D. T. H. van Tienoven, J. A. Foekens, P. N. Span, J. Bussink, and L. V. A. M. Beex Vascular Endothelial Growth Factor Independently Predicts the Efficacy of Postoperative Radiotherapy in Node-Negative Breast Cancer Patients Clin. Cancer Res., December 15, 2003; 9(17): 6363 - 6370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-S. Schrohl, M. Holten-Andersen, F. Sweep, M. Schmitt, N. Harbeck, J. Foekens, and N. Brunner Tumor Markers: From Laboratory To Clinical Utility Mol. Cell. Proteomics, June 1, 2003; 2(6): 378 - 387. [Full Text] [PDF]
|
|
|
|
|
|
V.-J. Bardou, G. Arpino, R. M. Elledge, C. K. Osborne, and G. M. Clark Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases J. Clin. Oncol., May 15, 2003; 21(10): 1973 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Stathopoulou, I. Vlachonikolis, D. Mavroudis, M. Perraki, Ch. Kouroussis, S. Apostolaki, N. Malamos, S. Kakolyris, A. Kotsakis, N. Xenidis, et al. Molecular Detection of Cytokeratin-19-Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance J. Clin. Oncol., August 15, 2002; 20(16): 3404 - 3412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Harbeck, R. E. Kates, and M. Schmitt Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination J. Clin. Oncol., February 15, 2002; 20(4): 1000 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Guidi, D. A. Berry, G. Broadwater, B. Helmchen, I. J. Bleiweiss, D. R. Budman, I. C. Henderson, L. Norton, and D. F. Hayes Association of Angiogenesis and Disease Outcome in Node-Positive Breast Cancer Patients Treated With Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil: A Cancer and Leukemia Group B Correlative Science Study From Protocols 8541/8869 J. Clin. Oncol., February 1, 2002; 20(3): 732 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Cornford, A. R. Dodson, K. F. Parsons, A. D. Desmond, A. Woolfenden, M. Fordham, J. P. Neoptolemos, Y. Ke, and C. S. Foster Heat Shock Protein Expression Independently Predicts Clinical Outcome in Prostate Cancer Cancer Res., December 1, 2000; 60(24): 7099 - 7105. [Abstract] [Full Text]
|
|
|
|
|
|
T. Mitsudomi, N. Hamajima, M. Ogawa, and T. Takahashi Prognostic Significance of p53 Alterations in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis Clin. Cancer Res., October 1, 2000; 6(10): 4055 - 4063. [Abstract] [Full Text]
|
|
|
|
|
|
K. Mokbel, A. C. A. Leris, J. Chang, T. J. Powles, D. C. Allred, S. E. Ashley, G. M. Clark, and M. Dowsett Predictors of Response to Chemotherapy J. Clin. Oncol., April 7, 2000; 18(7): 1601 - 1602. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Harvey, G. M. Clark, C. K. Osborne, and D. C. Allred Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer J. Clin. Oncol., May 1, 1999; 17(5): 1474 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Cameron and R. C. F. Leonard Re: erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer J Natl Cancer Inst, April 21, 1999; 91(8): 728 - 728. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Duffy, C. Duggan, H. E. Mulcahy, E. W. McDermott, and N. J. O'Higgins Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease Clin. Chem., June 1, 1998; 44(6): 1177 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Robbins p53 and Breast Cancer International Journal of Surgical Pathology, October 1, 1996; 4(2): 93 - 110. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||